American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 385.e1-385.e9 , April 2008

Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia

Presented at the 20th annual meeting of the Society for Pediatric and Perinatal Epidemiologic Research, Boston, MA, June 18-19, 2007.

  • Anne M. Lynch, MB, BCh, BAO, MSPH

      Affiliations

    • Department of Obstetrics and Gynecology, University of Colorado at Denver and Health Sciences Center, Denver, CO
    • Corresponding Author InformationReprints: Anne Lynch MB, BCh, BAO, MSPH, Department of Obstetrics and Gynecology, University of Colorado at Denver and Health Sciences Center, Department of Obstetrics and Gynecology, Mail Stop B198-5, Academic Office One, 12631 East 17th Avenue, PO Box 6511, Aurora, CO 80045.
    • ,
  • James R. Murphy, PhD

      Affiliations

    • Division of Biostatistics and Bioinformatics, National Jewish Medical and Research Center, Denver, CO
    • ,
  • Tim Byers, MD, MPH

      Affiliations

    • Department of Preventive Medicine and Biometrics, University of Colorado at Denver and Health Sciences Center, Denver, CO
    • ,
  • Ronald S. Gibbs, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Colorado at Denver and Health Sciences Center, Denver, CO
    • ,
  • Margaret C. Neville, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Colorado at Denver and Health Sciences Center, Denver, CO
    • ,
  • Patricia C. Giclas, PhD

      Affiliations

    • Department of Pediatrics, Division of Allergy and Immunology, National Jewish Medical and Research Center, Denver, CO
    • ,
  • Jane E. Salmon, MD

      Affiliations

    • Weill Medical College, Cornell University, New York, NY.
    • ,
  • V. Michael Holers, MD

      Affiliations

    • Department of Medicine and Immunology, University of Colorado at Denver and Health Sciences Center, Denver, CO

Received 13 June 2007 ,Revised 15 August 2007 ,Accepted 11 October 2007.

References 

  1. Dekker G, Robillard PY. Pre-eclampsia: is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol. 2007;76:8–16
  2. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22:203–212
  3. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5–15
  4. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002;160:1405–1423
  5. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  6. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194:1034–1041
  7. Moffett A, Hiby SE. How does the maternal immune system contribute to the development of pre-eclampsia?. Placenta. 2007;28(Suppl A):S51–S56
  8. Holers VM. Complement. In:  RR R editors. Principles and practive of clinical immunology. St Louis, MO: Mosby; 2001;
  9. Bulla R, Bossi F, Fischetti F, De Seta F, Tedesco F. The complement system at the fetomaternal interface. Chem Immunol Allergy. 2005;89:149–157
  10. Walport MJ. Complement (First of two parts). N Engl J Med. 2001;344:1058–1066
  11. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176:1305–1310
  12. Janeway C. Immunobiology: the immune system in health and disease. 6th ed. New York: Garland Science; 2005;
  13. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211–220
  14. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61:ii46–ii50
  15. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112:1644–1654
  16. Thurman JM, Kraus DM, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42:87–97
  17. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203:2165–2175
  18. Mao D, Wu X, Deppong C, et al. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity. 2003;19:813–822
  19. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799
  20. Lubchenco LO, Hansman C, Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics. 1966;37:403–408
  21. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions?. Am J Obstet Gynecol. 2006;194:921–931
  22. Haeger M, Unander M, Norder-Hansson B, Tylman M, Bengtsson A. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 1992;79:19–26
  23. Dekker G. The partner’s role in the etiology of preeclampsia. J Reprod Immunol. 2002;57:203–215
  24. Richani K, Soto E, Romero R, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17:239–245
  25. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000;287:498–501
  26. Giclas PC, Pinckard RN, Olson MS. In vitro activation of complement by isolated human heart subcellular membranes. J Immunol. 1979;122:146–151
  27. Walport MJ. Complement (Second of two parts). N Engl J Med. 2001;344:1140–1144
  28. Germain SJ, Sacks GP, Soorana SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol. 2007;178:5949–5956
  29. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin Obstet Gynaecol. 1992;6:439–460
  30. Holers VM. The complement system as a therapeutic target in autoimmunity. Clin Immunol. 2003;107:140–151
  31. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222–1226

 This study was supported by Grant K23 HD049684 from the National Institute of Child Health and Human Development and Newborn Hope Colorado (to A.M.L.) and National Institutes of Health Grant R01 AI 55007 (to V.M.H.).

 Cite this article as: Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol 2008;198:385.e1-385.e9.

PII: S0002-9378(07)02015-7

doi: 10.1016/j.ajog.2007.10.793

American Journal of Obstetrics & Gynecology
Volume 198, Issue 4 , Pages 385.e1-385.e9 , April 2008

Article Tools

* Image Usage & Resolution